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Abstract
Background: Smith-Magenis Syndrome is a contiguous gene syndrome in which the dosage sensitive gene has
been identified: the Retinoic Acid Induced 1 (RAI1). Little is known about the function of human RAI1.
Results: We generated the full-length cDNA of the wild type protein and five mutated forms: RAI1-HA 2687delC,
RAI1-HA 3103delC, RAI1 R960X, RAI1-HA Q1562R, and RAI1-HA S1808N. Four of them have been previously
associated with SMS clinical phenotype. Molecular weight, subcellular localization and transcription factor activity of
the wild type and mutant forms were studied by western blot, immunofluorescence and luciferase assays
respectively. The wild type protein and the two missense mutations presented a higher molecular weight than
expected, localized to the nucleus and activated transcription of a reporter gene. The frameshift mutations
generated a truncated polypeptide with transcription factor activity but abnormal subcellular localization, and the
same was true for the 1-960aa N-terminal half of RAI1. Two different C-terminal halves of the RAI1 protein (1038aa-
end and 1229aa-end) were able to localize into the nucleus but had no transactivation activity.
Conclusion: Our results indicate that transcription factor activity and subcellular localization signals reside in two
separate domains of the protein and both are essential for the correct functionality of RAI1. The pathogenic
outcome of some of the mutated forms can be explained by the dissociation of these two domains.
Background
A large fraction of genome variation between individuals
is comprised of submicroscopic copy number variation
of DNA segments (CNVs) [1-6]. Genomic disorders are
the clinical manifestation of pathological CNV. They are
frequent conditions (~1 per 1,000 births) and often
sporadic resulting from de novo rearrangements [7]. In a
subset of such conditions the rearrangements comprise
multiple unrelated contiguous genes that are physically
linked and thus have been referred to as contiguous
gene syndromes (CGS). An increasing number of CGS
are being described, each of them presenting a complex
and specific phenotype. Although several genes are
usually present in the segmental aneuploidy; only a
small subset of them conveys phenotypes as a function
of copy number alteration. These particular genes are
referred to as “dosage sensitive genes”.
The Smith-Magenis Syndrome, SMS, (OMIM#
182290) is a CGS associated with a microdeletion within
chromosome 17 band p11.2. SMS was first described in
1986 with a birth prevalence estimated at 1/25,000. The
clinical phenotype includes craniofacial abnormalities,
brachydactyly, self injurious behavior, sleep abnormal-
ities and mental retardation. Less commonly reported is
cleft palate, congenital heart defects, seizures, hearing
impairment and urinary tract anomalies [8]. Molecular
studies revealed a common deleted region of ~4 Mb in
the majority of SMS patients (>70-80%) [9-11]. Unusual
sized deletions (smaller or larger) were observed in
20-25% of patients [12-14]. By examining the break-
points in unusual sized deletions, the SMS critical
region was redefined to a ~950 kb interval, in which 15
genes and eight predicted genes were present [11-14].
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middle of the SMS critical region. Point mutations (non-
sense and frameshift as well as missense alleles) in RAI1
were identified in patients with clinical presentation of
SMS but no molecular deletion found by FISH [15-18],
suggesting that RAI1 is the dosage sensitive gene causa-
tive of SMS. Studies on mouse models [19] and humans
[20,21] indicate that RAI1 is likely the dosage sensitive
gene responsible for clinical features in the Potocki-
Lupski Syndrome (PTLS), (OMIM# 610883) a neuro-
behavioral disorder with autistic features that is caused
by reciprocal duplication of the 17p11.2 region [20-23].
The RAI1 gene consists of six exons [24] that span over
120 kb. The third exon contains >90% of the coding
region and it is within this exon where all mutations
have been identified to date.
Little is known about the cellular and developmental
role of RAI1. Expression of GT1, a splice variant of Rai1
was markedly up-regulated by treatment with retinoic
acid in a mouse carcinoma cell line P19 [25]. A poly-
morphic CAG repeat is present in the N-terminus of
the RAI1 protein, the length of which is associated with
the age of onset of spinocerebellar ataxia type 2 [26]
and the response to neuroleptic medication in schizo-
phrenia [27]. Moreover, RAI1 was recently associated
with non syndromic autism [28]. Bioinformatic analyses
have suggested that RAI1 might be a transcriptional reg-
ulator [15,16]. RAI1 contains several patches of 50%
similarity with TCF20, a transcriptional cofactor, and
these two genes have a similar gene structure. RAI1, in
both human and mouse, have two putative bipartite
nuclear localization signals (NLSs) predicted in silico,
and possesses a zinc finger like plant homeo domain
(PHD) in the C-terminus, which is also present in the
trithorax family of chromatin remodeling transcriptional
regulators [16]. In vitro studies of the murine Rai1 pro-
tein indicated that it can be transported to the nucleus
and has transactivation activity [29]. However, no sys-
tematic analysis of the human RAI1 protein has been
done. Here we describe the characterization of the wild
type RAI1 protein, plus five mutated forms of the pro-
tein, including four that have been associated with the
SMS clinical phenotype. Subcellular localization of the
resulting proteins and transcription factor activity were
studied for the wild type and mutant forms. Our results
indicate that the transcription factor activity and subcel-
lular localization of the protein are essential for the
pathogenic outcome of some of the mutated forms.
Results
The transcription factor activity of the murine Rai1
protein is dependent on the cell type
Human and mouse RAI1 share more than 80% in DNA
and amino acid homology sequence. Moreover, several
mouse models for SMS were developed and studied,
and they presented similar phenotypes to those found in
the SMS patients, reinforcing the idea of a comparable
function for murine and human RAI1 [30]. A previous
report by Bi et al., [29] showed that the murine Rai1
protein presented a mild transcription factor activity
and a nuclear subcellular localization. In order to corro-
borate previous findings and to set up the optimal con-
ditions for our studies of human RAI1, we subcloned
the murine Rai1 full-length cDNA kindly donated by
D r .J a m e sL u p s k i ,i n t od i f f e rent vectors that allowed us
to see the molecular weight, subcelullar localization and
transcription factor activity of the murine protein (figure
1). The expected 201.5 kDa molecular weight for the
murine protein was similar to the obtained molecular
weight (213 kDa) (figure 1B), as well as the nuclear sub-
cellular localization (figure 1C). It was previously
reported that Rai1 has relatively weak transactivation
activity in transfected HeLa cells in comparison to other
transcription factors [29]. Neurobehavioral abnormalities
are the prevalent clinical presentation in SMS patients.
Based on this we wanted to examine whether Rai1 has a
different transactivation activity in cells derived from
murine neuroblastoma, the Neuro-2a cell line. In order
to do this, full-length Rai1 was fused with the GAL4
DNA binding domain (GAL4-BD) and co-transfected
into HeLa and Neuro-2a cells with a luciferase reporter
plasmid which contains five tandem repeats of yeast
GAL4-binding sites upstream of the luciferase gene, plus
a plasmid containing the beta galactosidase gene to con-
trol transfection efficiency. The results showed that the
transcription factor activity in HeLa cells is 2.2 +/- 1.5
folds over the empty vector and in Neuro-2a cells is
61.3 +/- 11.2 indicating that the murine protein has a
transactivational activity several times stronger in the
Neuro-2a cell line than in HeLa cells, suggesting that
there is a specific machinery in neuronal cells that
may be related to Rai1 transcription factor activity
(figure 1D).
Human RAI1 is a nuclear protein with transcription factor
activity
In a first attempt to understand and characterize the
function of human RAI1 we generated the full-length
cDNA coding for the wild type protein. The full-length
cDNA was obtained as described in Material and Meth-
ods. The final full-length sequence is the same as the one
reported in NM_030665 with SNP A/G at position 1992.
In order to have an easy way to identify the transfected
RAI1 from the endogenous protein, an HA tag was
added in the 3’ end (figure 1A). Since we found that Rai1
activity was dependent of cellular type, we performed all
our studies in mouse Neuro-2a neuroblastoma cells.
Neuro-2a cell line was preferred over the SH-SY5Y
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gin, since the human ones grow at an extremely slow rate
and making them very difficult to transfect. In order to
determine the molecular weight of the protein, both
clones the RAI1 and RAI1-HA cDNA were transiently
transfected, and 48 h post-transfection the cell lysate was
r u ni na1 0 %S D S - P A G Eg e l .T h ep r e d i c t e din silico
molecular weight for RAI1 is 203 kDa. As can be
observed in figure 1B, the molecular weight of both pro-
teins is ~260 kDa, and the addition of the HA tag is not
inducing instability of the resulting protein. The
difference between the molecular weight predicted and
the obtained could be explained by post-translational
modifications (PTM) for example glycosylations. We
found several predicted glycosylation sites on the first
amino-terminal half of RAI1 (analysis in NetOGlyc 3.1
server, EXPASY Tools, http://www.expasy.org) [31].
To prove if the human protein has transcription factor
activity, we subcloned the RAI1 and RAI1-HA full-length
cDNA into a GAL4-binding domain vector (pCMV-BD,
Stratagene). It is important to note that the presence of
the GAL4-binding domain is enough to localize the
Figure 1 Generation of murine and human -HA tagged RAI1 and molecular evaluation of the resulting proteins. A) Schematic
representation of mouse (Rai1) and human (RAI1) genomic and protein structure. In blue is represented the Poly-Gln domain, in yellow: Poly-Ser
domains, in black: in silico described NLS, in slanted lines: the PHD domain. The coding sequence for HA epitope (represented in red) was added
by PCR at the 3’ end of full-length cDNA. B) Cells transfected with either mouse Rai1-HA plasmid (Rai1-HA), the human RAI1 plasmid, RAI1 or
RAI1-HA, an empty vector (e/v) or untransfected cells (u/t) were lysed and a western blot analysis was performed with an anti HA antibody
(aHA). The molecular weight of the resulting proteins is depicted. The anti b-tubulin antibody (ab -tubulin) was used as loading control. C)
Neuro-2a cells were transiently transfected with the mouse Rai1-HA plasmid (Rai1-HA), the human RAI1 and RAI1-HA plasmids.
Immunofluorescence with an antibody that recognized the HA tag (aHA) (red) and an antibody that recognizes the first 30 aa of RAI1 (aRAI1)
(green) are shown. Untransfected cells in the same slide were used as negative control. Nuclei were stained with DAPI. The table represents the
subcellular localization observed for 200 counted cells positive for immunodetection. D) Transactivational activity. The fold of luciferase activation
is represented for the empty vector (gray), Neuro-2a cells transfected with mouse Rai1-HA (black), human RAI1 (light blue), and RAI1-HA (light
green) and HeLa cells transfected with Rai1-HA (white). Values represent mean +/- SEM.
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plus the reporter gene was carried out and 48 h post-
transfection the cells were lysed and the activity of the
luciferase reporter gene was measured. As can be seen in
figure 1D, the expression of the wild type RAI1 and RAI1-
HA derives in an 67.5 +/- 31.8 and 58.8 +/- 11.1 fold
increase of the luciferase activity respectively, indicating
that the human protein presented transcription factor
activity and that the addition of the HA tag did not inter-
fere with the activity of the resulting protein. RAI1 has a
bipartite nuclear localization signal predicted by infor-
matics analysis [15]. Nuclear subcellular localization was
found for both, the RAI1 and RAI-HA proteins (figure 1C)
at 36 h post-transfection and this result was confirmed
with two different antibodies, one that recognized an epi-
tope within the first 30 amino acids in the N-terminus
portion of the RAI1 protein and the anti HA antibody,
which recognized the C-terminus end in the RAI1-HA
clone. These results indicate that the human RAI1 protein,
with or without the HA tag, has a nuclear localization and
the ability to activate the transcription of a reporter gene.
The N-terminal truncated RAI1 polypeptides retain the
transcription factor activity but localize in the cytoplasm
Most Smith-Magenis cases present a deletion in chro-
mosome 17p11.2 that causes the haploinsufficiency of
the RAI1 gene. However, in some patients heterozygous
mutations have been found within the RAI1 coding
region. In order to study how these mutations can be
detrimental we analyzed two independent deletions of
one C within the coding region, the RAI1 2687delC (not
found yet in any patient and spontaneously originated in
our laboratory) and the RAI1 3103delC [18] (figure 2A).
Theoretically in both cases the deletion of a C within
the C tract will result in a frameshift, misincorporation
of amino acids and a subsequent premature stop codon.
In the case of RAI1-HA 2687delC a misincorporation of
53 amino acids followed by a stop codon is expected,
while in the RAI1-HA 3103delC protein the misincor-
poration will be 28 amino acids. In order to avoid the
possible interference of the misincorporated amino acids
in the following studies we also generated the RAI1
R960X mutation [18], where an arginine is replaced by a
stop codon in the coding sequence generating a trun-
cated protein, with no addition of extra amino acids. In
order to determine the molecular weight of the resulting
proteins, the three clones were transiently transfected,
and 48 h post-transfection the cell lysate was run in a
10% SDS-PAGE gel. The predicted molecular weights
for the proteins originated by RAI1-HA 2687delC, RAI1-
HA 3103delC and RAI1 R960X are 102, 114 and 103
kDa respectively. As can be observed in figure 2B, the
obtained molecular weight of the three truncated pro-
teins was ~150, 170 and 136 kDa respectively. These
differences coincide with the predicted versus observed
molecular weight differences found for the wild type
protein with or without the HA tag, suggesting that the
alleged modifications reside in the N-terminal half of
RAI1.
We evaluated the transcription factor activity for the
truncated products by subcloning the three mutant
forms cDNA into the pCMV-BD vector and posterior
transfection of each clone plus the reporter gene into
Neuro-2a cells. Forty eight hours post-transfection the
cells were lysed and the activity of the luciferase repor-
ter gene was measured. As can be seen in figure 2C, all
truncated proteins gave an increment of 233.2 +/- 19.2
(for RAI1 2687delC), 179.1 +/- 24.1 (for RAI1
3103delC), and 282.5 +/- 23.8 (for RAI1 R960X), in per-
centage of activation in comparison with the 100% of
the wild type, indicating that the truncated polypeptides
retained the transcription factor activity. All the trun-
cated proteins showed a significant increased percentage
of transcription activation when compared to the wild
type protein (P value ≤ 0.01). The following step was to
evaluate the subcellular localization of the truncated
fragments in the absence of the GAL4-binding domain
since the presence of this domain is enough to localize
any protein to the nucleus [32]. The resulting truncated
polypeptides would not include the hypothetical Nuclear
Localization Signals (NLSs). Cytoplasmatic subcellular
localization was found for all the
RAI1-HA 2687delC, RAI1-HA 3103delC and RAI1
R960X polypeptides (figure 2D). All together these
results indicate that RAI1-HA 2687delC, RAI1-HA
3103delC and RAI1 R960X are generating truncated
polypeptides that retain the transcription factor activity.
However, they are not localized in the nucleus but in
the cytoplasm of cells.
Nuclear localization signals are situated in the C-terminus
of the human RAI1 protein
In order to verify that the C-terminal portion of the
RAI1 protein is the one retaining the nuclear localiza-
tion signals we generated two different fragments, one
beginning at Met 1038 and the other beginning at Met
1229 of the RAI1 protein. The difference between them
contains the sequence that was assigned as the bipartite
NLS by in silico methods [15]. Both C-terminal halves
were generated as described in Material and Methods
(figure 3A). In order to determine the molecular weight
of the resulting proteins, both clones were transiently
transfected, and 48 h post-transfection the cell lysate
was run in a 10% SDS-PAGE gel. As can be observed in
figure 3B, the molecular weight of both truncated pro-
teins was ~115 kDa and 85 kDa respectively as pre-
dicted; and interestingly these results differ from those
obtained with the other proteins analyzed further
Carmona-Mora et al. BMC Molecular Biology 2010, 11:63
http://www.biomedcentral.com/1471-2199/11/63
Page 4 of 12supporting the possibility of a specific PTM in the N-
terminal half of RAI1. We evaluated the transcription
factor activity for the C-terminal halves of RAI1 by sub-
cloning them into the pCMV-BD vector with posterior
transfection of each clone plus the reporter gene into
Neuro-2a cells. As can be seen in figure 3C, both C-
terminal halves of RAI1 were unable to activate the
transcription of the luciferase reporter gene, since no
luciferase activity could be measured in any of the
assays. To evaluate the subcellular localization of the
truncated fragments, both halves were transfected into
Neuro-2a cells and the subcellular localization assayed
with anti HA antibody. As can be observed, both halves
were found in the nucleus suggesting the presence of
extra NLS (figure 3D). Altogether these results indicate
that the N-terminal region of the human protein has the
transcription factor activity and it is in the C-terminal
half that the nuclear localization signaling resides.
No alterations were found for RAI1 Q1562R and RAI1
S1808N mutants
As we mentioned earlier, there are only rare cases with
patients with Smith-Magenis Syndrome associated with
heterozygous missense mutations in the RAI1 coding
Figure 2 Evaluation of truncated proteins. A) Schematic representation of the two truncated RAI1 proteins generated by the deletion of a C
in positions 2687 and 3103, plus RAI1 R960X. In blue is represented the Poly-Gln domain, in yellow: Poly-Ser domains, in black: in silico described
NLS, in slanted lines: the PHD domain. The coding sequence for HA epitope is represented in red. B) Molecular weight for all truncated proteins
was calculated by western blot analysis utilizing anti RAI1 antibody in transfected Neuro-2a cells. The molecular weight obtained for 2687delC,
3103delC and R960X is indicated. e/v: cells transfected with empty vector; u/t: untransfected Neuro-2a cells. C) The percentages of activation for
the proteins 2687delC (white), 3103delC (grey) and R960X (light grey) are represented. The wild type (black) is considered as 100% of
transcription activity. Values represent mean +/- SEM. (*: P ≤ 0.01). D) Immunofluorescence was performed with anti RAI1 antibody (green).
Nuclei were stained with DAPI. The table represents a summary of the subcellular localization found in 200 cells. a = antibody against RAI1.
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found: RAI1 Q1562R and RAI1 S1808N [17]. In order to
investigate if these mutations were affecting the stability,
subcellular localization or transcription activity function
of the RAI1 protein we generated both mutations as
described in Material and Methods (figure 4A). To
determine the molecular weight of the resulting pro-
teins, both clones were transiently transfected, and 48 h
post-transfection the cell lysate was run in a 10% SDS-
PAGE gel. As can be observed in figure 4B, the molecu-
lar weight of both proteins is ~260 kDa similar to the
wild type protein. Moreover, none of the mutations
seem to give the protein any instability, since the rela-
tive signal for both mutants and the wild type RAI1
protein utilizing b-tubulin as loading control protein is
the same for all of them. Although there could be differ-
ences between transfection efficiency of the samples, we
have found by densitometric analysis of bands from
different western blots (n = 3), that the ratio RAI1/
b-tubulin is the same for wild type, RAI1-HA Q1562R
and RAI1-HA S1808N (~1 in all cases) (data not
shown).
For both mutants we evaluated the transcription factor
activity, in the same way that was previously done for
the other proteins. As can be seen in figure 4C, both
RAI1-HA Q1562R and RAI1-HA S1808N mutated
proteins can give an increment of 120.5 +/- 20.4 and
113.7 +/- 8.6 percentage of activation of luciferase
Figure 3 Evaluation of the proteins generated containing the C-terminal half of RAI1. A) Schematic representation of the construction of
proteins 1038-end and 1229-end that were generated by PCR. Both proteins are tagged with the HA peptide on the C-terminal end. In blue is
represented the Poly-Gln domain, in yellow: Poly-Ser domains, in black: in silico described nuclear localization signals, in slanted line: the PHD
domain. B) The molecular weight for both proteins was obtained by transfecting them in Neuro-2a cells and then a western blot analysis was
performed with anti HA antibody. Molecular weight for the proteins 1038-end and 1229-end are depicted and also are shown the controls with
only the transfection of empty vector (e/v) and untransfected Neuro-2a cells (u/t). C) The graphic represents the percentage of activation for
1038-end protein (grey) and 1229-end protein (white) compared to the wild type full-length protein (black). Values represent mean +/- SEM.
(* depicts statistically significant differences, p ≤ 0.0002). D) Each plasmid was transfected in Neuro-2a cells and an immunofluorescence was
performed with anti HA antibody. Nuclei staining were made with DAPI. The table shows subcellular localization for 200 cells positive for anti
HA. a = antibody against HA.
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as 100%. This is similar to what was found for the wild
type RAI1-HA protein, indicating that the mutated poly-
peptides retained the transcription factor activity. We
next evaluated the subcellular localization of the
mutated proteins, and nuclear localization was found for
both of them (figure 4D). All together these results indi-
cate that RAI1 Q1562R and RAI1 S1808N mutations are
not affecting the stability, transcription factor activity or
subcellular localization of the protein.
Discussion
Alterations in the RAI1 gene have been associated with
Smith-Magenis and Potocki-Lupski Syndromes whose
clinical presentation includes autistic features, obsessive-
compulsive behaviors, attention deficit, developmental
delay, mental retardation, EEG abnormalities, sleep dis-
turbances, self-injurious and maladaptive behaviors,
among others [19-21]. In addition to this, RAI1 gene
was associated with spinocerebellar ataxia (SCA2) [26],
neuroleptic response in patients with schizophrenia [27],
neurobehavioral traits manifested in SMS patients with
RAI1 loss-of-function alleles [33-46] and non syndromic
autism [28]. Despite its relationship with these impor-
tant traits, there is lack of information about the mole-
cular function of human RAI1.
Several heterozygous nucleotide variations in RAI1
gene have been found in SMS patients without 17p11.2
Figure 4 Molecular evaluation of two point mutations associated with SMS. A) Schematic representation RAI1 Q1562R and RAI1 S1808N. In
blue is represented the Poly-Gln domain, in yellow: Poly-Ser domains, in black: in silico described nuclear localization signals, in slanted line: the
PHD domain. The coding sequence for HA epitope is represented in red. B) The molecular weight of mutated proteins was calculated in Neuro-
2a cells by western blotting with anti RAI1 antibody. The obtained molecular weight is depicted and also the controls for the immunoreactivity
are shown (e/v: extracts transfected only with the empty vector and u/t represents untransfected cells control). C) The percentage of the
reporter transcription activation is shown for RAI1-HA Q1562R (white) and RAI1-HA S1808N (grey) compared to RAI1-HA wild type protein (black).
Values represent mean +/- SEM. D) Each plasmid was transfected in Neuro-2a cells and immunofluorescence was performed with anti RAI1
antibody and nuclei staining is shown with DAPI. The table represents subcellular localization of 200 cells immunodetected with anti RAI1
antibody. a = antibody against.
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sense mutations besides deletions of one or multiple
nucleotides [15-18,43].
Within the RAI1 gene coding sequence there are sev-
eral mononucleotide repeats. Intriguingly all five single
base pair frameshift mutations found in the RAI1 gene
associated with the SMS phenotype were in the C-tracts
although the number of G-tracts in the RAI1 coding
region is comparable with the C-tracts [18]. Interest-
ingly, in our laboratory a spontaneous deletion of a C in
a four C-tract at the position 2687 occurred, providing
further evidence that polyC-tract may be a preferential
target for frameshift mutations in RAI1.
Here we generated and studied the full-length cDNA
of human wild type RAI1 and five mutated forms of the
protein. Four of them previously associated with SMS.
As deletions appear to be a very frequent event in the
RAI1 coding region, we also included in this study the
spontaneously generated 2687delC. In order to comple-
ment these studies, we have constructed two smaller
proteins corresponding to the residues 1038-1906 and
1229-1906.
It was previously reported that mouse Rai1 has mod-
erate transactivational activity in HeLa cells [29]. Here
we confirmed those previous findings and showed that
Rai1 has a stronger transactivation activity in Neuro-2a
cells, the neuronal derived cell line. These results sug-
gest specificity in the transcription machinery that RAI1
could be part of and further indicate the importance of
its role in neuronal derived tissues, since RAI1 is a
dosage sensitive gene involved in neurobehavioral
phenotypes.
Here we report that the wild type human RAI1 pro-
tein has transcription factor activity. Our studies of
truncated proteins associated with 2687delC and
3103delC frameshifts plus R960X mutant, showed tran-
scription factor activity significantly higher than the wild
type protein for the resulting polypeptides. Moreover,
the analysis of the two smaller proteins corresponding
to the residues 1038-1906 and 1229-1906 showed no
capability of activating transcription themselves. Accord-
ing to our results, the human RAI1 showed that the
most important region of the protein for stimulating
transcription is the N-terminal half, until residue 1034.
From the residue 1038 to the end of RAI1 a fragment
able to regulate the transactivational activity of the pro-
tein or the machinery associated may be present, since
all truncated proteins showed a significant increase in
transcription activity when compared to the full-length
protein. In the N-terminal region, corresponding
approximately to the first half of the protein, there is a
homology of ~84% between human and murine RAI1.
For the murine Rai1 protein, putative transactivation
domains were mapped by fusion of different regions to
GAL4-BD [29]. The polypeptides containing residues
1-582 or encompassing residues 583 to 1142 have been
shown to have transactivation activity while no transac-
tivation activity was found in the region containing the
remaining half; consistent with what is reported here for
the human protein.
By bioinformatics analysis two putative bipartite
nuclear localization signals (NLSs) were defined for
RAI1 at positions 1113 and 1176 aa respectively [15].
Despite that we cannot discard the participation of the
previously described NLS in the nuclear localization of
the RAI1 protein, our results indicate that there is a
nuclear localization signal that resides between 1229 aa
to the end since the two smaller proteins 1038-1906 and
1229-1906 were able to localize in the nucleus; while the
two N-terminal polypeptides were retained in the cyto-
plasm. These results suggest the presence of another
fragment within the C-terminal half of RAI1 that modu-
lates the nuclear localization of the protein. Accordingly,
in vitro studies of the murine Rai1 protein indicated
that it can be transported to the nucleus and that the
nuclear localization signals reside between the 1134-
1164 and 1203-1229 aa. Besides, on the C-terminal half
of Rai1 there are other regions that are also able to
transport the protein to the nucleus [29].
Taking these results together, we can define two clear
domains in RAI1: an N-terminal half critical for its
transactivational activity and a C-terminal half responsi-
ble for its nuclear transportation. In addition, to the C-
terminus of both human and mouse RAI1, a zinc finger
like plant homeo domain (PHD), which is also present
in the trithorax family of chromatin remodeling tran-
scriptional regulators was defined [16]. All these differ-
ent domains are depicted in figure 5.
The truncated proteins generated by mutations
2687delC, 3103delC and R960X showed to be functional
and moreover, they have an increased capability for acti-
vating the transcription when compared to the wild type
protein. However, none of the resulting polypeptides were
able to localize in the nucleus, suggesting that this inability
(even retaining transcription factor activity) would be the
main pathological way of action for these mutations.
Finally, there are spare cases of SMS patients with
mutations in the RAI1 gene. We generated two indepen-
dent mutations, RAI1 Q1562R and RAI1 S1808N. No
abnormal molecular weight, subcellular localization or
transcription factor activity were found for any of these
mutants, suggesting that they may be implicated in the
association with other proteins or some other functional
role of RAI1 that is not known to date.
Conclusion
We were able to demonstrate that the human wild type
protein has transcription factor activity, and is able to
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transcription factor domain within the first 1034 aa and
that the nuclear localization signals reside in the second
half the protein. Altogether the analysis of the mutant
proteins indicates that both halves are necessary for the
correct subcellular localization and function of the pro-
tein, and that other molecular/functional role of RAI1
remains unknown.
Methods
Plasmid Constructs
The full-length clone of murine Rai1 was kindly pro-
vided by Dr. James Lupski, Department of Molecular &
Human Genetics, Baylor College of Medicine, Houston,
Texas, USA. The sequence of influenza virus hemagglu-
tinin epitope (HA) was added to the 3′ extreme to gen-
erate a tag by PCR using pCR3.1 Rai1 as template, with
the primers Forward: GCCTCATCCTGAGAAGCAAC
and Reverse: AAGTCTAGATTAAGCGTAATCTG-
GAACATCGTATGGGTACAACGGCAGCCTCTTA
TGTTTG. The reverse primer contains the last
22 nucleotides of Rai1 cDNA without its stop codon,
the coding sequence of hemagglutinin epitope, followed
b yas t o pc o d o na n da nXbaI restriction site. The pro-
duct of the reaction was purified and ligated into
pGEM-T easy vector (Promega) and sequenced. In
order to obtain the full-length Rai1-HA clone this PCR
fragment was subcloned into the pCR3.1 Rai1 between
the AccI and XbaI sites.
As a first step to obtain the complete RAI1 cDNA a
PCR product was generated by amplification of a
human brain cDNA library with the following primers:
Forward: GGCCTGGTAAATGTGGGCACCGGG and
Reverse:
Figure 5 Summary of the results and definition of two domains in the structure of RAI1.B yin silico analyses, several domains have been
found for RAI1: a polyglutamine tract at the N-terminal of the protein (in blue), two polyserine domains (in yellow), a PHD domain at the
C-terminal of RAI1 (in slanted lines) and two putative nuclear localization signals (in black). The schematic representation of all the mutants
analyzed in this study is shown. An asterisk represents the missense mutations. Two defined domains are depicted.
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Page 9 of 12AAGGCGGCCGCTTAAGCGTAATCTGGAACATCG-
TATGGGTACGGCAGCCTCTTATGTTTGGGAC. The
reverse primer was designed to add the influenza virus
hemagglutinin epitope tag (HA) and the NotIr e s t r i c t i o n
site at the 3′ extreme. Finally, the partial 5′ end cDNA
RAI1 clone (KIAA1820, Kazusa DNA Research Institute,
Japan) was ligated with the ~1.5 kb fragment that con-
tained the 3′ end of the cDNA with BamHI and NotI
enzymes. The complete RAI1 cDNA clone was totally
sequenced.
Three different point mutants were generated by site-
directed mutagenesis by PCR with the kit QuickChange
Site-Directed Mutagenesis XL Kit (Stratagene) utilizing
the following primers: for the mutation A4685G, For-
ward: GCGACGACGACGGCAGCAGGTGCTG and
Reverse: CAGCACCTGCTGCCGTCGTCGTCGC; for
the mutation G5423A, Forward: CAAACATGAGTG-
CAACAAGGAGGCTC and Reverse: GAGCCTCCT
TGTTGCACTCATGTTTG, for the deletion 3103delC,
Forward: CTGCACAGGGCCCCCCAGGGACAGATG-
GAA and Reverse: CTTCCATCTGTCCCTGGGGGG
CCCTGTGCAG. The deletion 2687delC was a sponta-
neous deletion found during the sequencing. The cDNA
for the truncated protein R960X was generated by PCR
with the following primers, Forward:C T G A C C G G T
GGCTGGAGGAC and Reverse: TGGTGGAATCCC
CTGGAGCTCCTACTCC. The product contains a stop
codon instead of base 2878. This fragment was sub-
cloned into full-length RAI1 cDNA with the enzyme
SacI. All clones were verified by DNA sequencing.
Two C-terminal fragments of the RAI1 protein were
generated using the following primers: for the fragment
1038-1915, Forward: GGGACAGATGGAAGGGGC
TGG and for the fragment 1229-1915, Forward:G T C G
GCCTTCATGGCGCCG. Both amplification reactions
were performed with the same primer reverse used for
generating the full-length clone, detailed above, which
contains the HA tag and the NotI restriction site at the
3′ extreme. PCR products obtained were fully verified by
DNA sequencing.
For expression analysis, the cDNAs of RAI1 wild type
and mutant forms were subcloned in pALTER-MAX
vector (Promega).
Accession numbers
For KIAA1820 [GenBank: AB058723], Mouse Rai1
[GenBank: NM_009021 and Swiss-Prot: Q61818]. For
Human RAI1 [GenBank: NM_030665 and Swiss-Prot:
Q7Z5J4].
Cell Culture
Neuro-2a and HeLa cells were grown in Dulbecco’s
Modified Eagle Medium supplemented with 10% fetal
bovine serum, penicillin (100 units/ml), streptomycin
(100 μg/ml) (Gibco by Invitrogen) at 37°C with 5% CO2
until 95% confluence was attained.
Immunofluorescence and Western blot analysis
To study the expression of the proteins generated,
Neuro-2a cells were transfected using Lipofectamine
2000 (Invitrogen), with the mouse plasmid pCR3.1 Rai1-
HA and human constructs pALTER-MAX RAI1-HA
wild type, RAI1-HA Q1562R, RAI1-HA S1808N, RAI1
R960X, RAI1-HA 2687delC, RAI1HA 3103delC, RAI1HA
1038-1915 and RAI1HA 1229-1915. All transfections
were performed according to manufacturer’s protocol.
For immunofluorescence, cells were fixed 36 h after
transfection with 4% paraformaldehyde followed by per-
meabilization with 0.1% Triton X-100 in PBS. Subcellu-
lar localization of RAI1-HA wild type and mutant forms
of the protein were detected using rabbit anti human
RAI1 polyclonal antibody (1:200, ab58658 Abcam)
whose epitope locates at the amino-terminal of RAI1. A
secondary antibody conjugated to Alexa fluor 488
(1:500) was used. Cells were mounted in a medium with
DAPI (Vector Laboratories).
For western blot analysis, total protein extracts were
prepared 48 h after transfection. Cells were lysed in 100
μl of protein extraction and loading buffer (2% SDS,
2 M Urea, 10% Glycerol, 10 mM Tris pH 6.8, 0.002%
Bromophenol Blue and 10 mM DTT) plus 1:200 pro-
tease inhibitor cocktail (SIGMA). The samples were
homogenized passing 20 times through a syringe and
warmed up to 95°C for 5 minutes. 25 μl of each cell
lysate was loaded onto 10% SDS-polyacrylamide gels
with Tris/glycine running buffer and transferred to a
0.2 μm polyvinylidene fluoride (PVDF, Bio-Rad) mem-
brane. Immunodetection was performed using rabbit
anti human RAI1 polyclonal antibody (1:1000, Abcam)
and rabbit anti b-tubulin (1:1000, sc-9104 Santa Cruz).
Results were visualized by chemiluminiscence.
The detection of murine Rai1-HA and proteins 1038-
1915 and 1229-1915 was done with anti HA high affi-
nity antibody (1:5000 for Western blot and 1:1000 for
immunofluorescence clone 3F10, Roche).
Reporter gene assays
Transient transfections in Neuro-2a cells were per-
formed in 35 mm plates. The amounts of plasmid DNA
used were according to manufacturer’s protocol. GAL4-
BD fusions of mouse and human RAI1 wild type and all
of its mutant forms were co-transfected with the lucifer-
ase reporter plasmid pFR-Luc (Stratagene) and the
b-Galactosidase expression plasmid pSV-b-Galactosidase
(for normalization of the transfection efficiency). Forty
eight hours post-transfection, cells were lysed and luci-
ferase assays were performed with Luciferase Assay Kit
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The Relative Lights Units (RLUs) were measured in
duplicate in a Syrius Luminometer (Berthold Detection
Systems).
b-Galactosidase activities were measured with 810 μl
of b-Galactosidase buffer (60 mM Na2HPO4,4 0m M
NaH2PO4,1 0m MK C l ,1m MM g C l 2 and 50 mM
b-mercaptoethanol) for 50 μlo fc e l ll y s a t e sp l u s1 6 0μl
ONPG reagent (60 mM Na2HPO4,40 mM NaH2PO4
and 4 mg/ml ONPG (o-Nitrophenyl-b-D-Galactopyra-
noside). Incubations were performed at 30°C, reactions
were stopped by adding 250 μlo fN a 2CO3 1M .T h e
absorbance was read at 420 nm. Each cell assay was
carried out in duplicate.
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